Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia.

University of the Pacific School of Pharmacy and San Diego VA Medical Center, San Diego, California 92161, USA.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.45). 07/2007; 51(7):2582-6. DOI: 10.1128/AAC.00939-06
Source: PubMed

ABSTRACT We examined the relationship between the time to clearance of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia while patients were receiving vancomycin therapy and the in vitro bactericidal activity of vancomycin. Vancomycin killing assays were performed with 34 MRSA bloodstream isolates (17 accessory gene regulator group II [agr-II] and 17 non-agr-II isolates) from 34 different patients with MRSA bacteremia for whom clinical and microbiological outcomes data were available. Vancomycin doses were prospectively adjusted to achieve peak plasma concentrations of 28 to 32 mug/ml and trough concentrations of 8 to 12 microg/ml. Bactericidal assays were performed over 24 h with approximately 10(7) to 10(8) CFU/ml in broth containing 16 microg/ml vancomycin. The median time to clearance of bacteremia was 6.5 days for patients with MRSA isolates demonstrating > or =2.5 reductions in log(10) CFU/ml at 24 h and >10.5 days for patients with MRSA isolates demonstrating <2.5 log(10) CFU/ml by 24 h (P = 0.025). The median time to clearance was significantly longer with MRSA isolates with vancomycin MICs of 2.0 microg/ml compared to that with MRSA isolates with MICs of < or =1.0 microg/ml (P = 0.019). The bacteremia caused by MRSA isolates with absent or severely reduced delta-hemolysin expression was of a longer duration of bacteremia (10 days and 6.5 days, respectively; P = 0.27) and had a decreased probability of eradication (44% and 78%, respectively; P = 0.086). We conclude that strain-specific microbiological features of MRSA, such as increased vancomycin MICs and decreased killing by vancomycin, appear to be predictive of prolonged MRSA bacteremia while patients are receiving vancomycin therapy. Prolonged bacteremia and decreased delta-hemolysin expression may also be related. Evaluation of these properties may be useful in the consideration of antimicrobial therapies that can be used as alternatives to vancomycin for the treatment of MRSA bacteremia.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The indications for vancomycin prophylaxis to prevent Methicillin-resistant Staphylococcus aureus (MRSA) surgical site infections are increasing. The recommended dose of vancomycin has traditionally been 1 gram intravenous. However, the increasing prevalence of obesity in our population coupled with increasing resistance of MRSA to vancomycin has resulted in recent recommendations for weight-based dosing of vancomycin at 15mg/kg. We hypothesize that the standard one gram dose of vancomycin is inadequate to meet the recently recommended dosage of 15mg/kg.
    The Iowa orthopaedic journal 01/2014; 34:111-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The reproducibility of vancomycin and daptomycin MICs, measured by broth microdilution (BMD) and Etest, was prospectively assessed for 10 MRSA isolated from the blood of patients on vancomycin therapy. Isolates were tested at the time of isolation from blood, and following 5, 10, and 20 subcultures and 1, 3, 6, and 12 months storage at -70°C. MICs were determined by Etest and by BMD using two different manufacturers of cation-adjusted Muller-Hinton broth (CA-MHB; BBL and Difco) and using three different drug powders: vancomycin from Sigma, vancomycin from Novation, and daptomycin from Cubist. Antimicrobial concentrations tested were 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5 and 4.0 μg/ml. Two isolates were vancomycin-intermediate and daptomycin non-susceptible, and two isolates had reduced susceptibility to vancomycin (BMD MIC 1.5 or 2.0 μg/ml). Vancomycin MICs were significantly higher in BBL CA-MHB vs. Difco CA-MHB, and with Sigma vs. Novation vancomycin powder. Daptomycin MICs were also significantly higher in BBL CA-MHB. Etest MICs were significantly higher than those obtained by BMD for vancomycin, but not for daptomycin. The average precision of vancomycin BMD MICs when analyzing 20 results was ±1.10-fold log2 dilutions, and for daptomycin (10 results) was ±1.67-fold. Average precision for Etest was ±1.11-fold for vancomycin and ±1.16-fold for daptomycin. No significant change in MICs was noted following 5, 10, or 20 subcultures, nor following up to 6 months frozen storage. However, vancomycin MICs alone were significantly lower (0.74 fold) following 12 months frozen storage. From these data, despite CA-MHB and antimicrobial powder variation, MIC result precision was below 0.5 log2 dilutions in a single laboratory, suggesting that testing inter-dilution MICs (e.g., MICs between serial 2-fold dilutions) is a possibility. A more accurate method for measuring vancomycin MIC results is thus possible, but further standardization of BMD testing would be required to achieve this goal.
    Journal of clinical microbiology. 08/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Elevated minimum inhibitory concentrations (MICs) of vancomycin against meticillin-resistant Staphylococcus aureus (MRSA) and the emergence of heteroresistant S. aureus strains have led to increased use of anti-MRSA antibiotics other than vancomycin. Ceftaroline fosamil is a novel cephalosporin with activity against MRSA, but there are limited clinical data on its use for MRSA bacteraemia (MRSAB) and against strains exhibiting high vancomycin MICs (2–4 μg/mL). This multicentre, retrospective, case–control study compared the microbiological and clinical effectiveness of ceftaroline used after vancomycin failure with that of vancomycin-treated controls for the treatment of MRSA with vancomycin MICs ≥ 2 μg/mL. In total, 32 patients were matched 1:1 with respect to vancomycin MIC, age and origin of bacteraemia. In the ceftaroline group, patients received prior MRSA therapy for a median of 5 days [interquartile range (IQR), 3–15.8 days] prior to switching to ceftaroline. Median time to eradication of MRSA was significantly less after treatment with ceftaroline compared with vancomycin [4 days (IQR, 3–7.5 days) vs. 8 days (IQR, 5.8–19.5 days); P = 0.02]. Both clinical success at the end of treatment and recurrence of MRSA at Day 7 were trending towards being inferior in the vancomycin group, although the results did not attain statistical significance [81% vs. 44% (P = 0.06) and 6% vs. 38% (P = 0.08), respectively]. Ceftaroline added at the point of vancomycin failure resolves MRSAB more rapidly and with a higher rate of clinical success, therefore ceftaroline should be considered as an alternative for these difficult-to-treat infections.
    International Journal of Antimicrobial Agents 09/2014; · 4.26 Impact Factor

Full-text (2 Sources)

Available from
Feb 13, 2015